Chemistry Reference
In-Depth Information
82. Kestur, U.S., Van Eerdenbrugh, B., and Taylor, L.S. (2011) Influence of polymer chemistry
on crystal growth inhibition of two chemically diverse organic molecules.
CrystEngComm
,
13(22):6712-6718.
83. Ilevbare, G.A., Liu, H., Edgar, K.J., and Taylor, L.S. (2013) Impact of polymers on crystal
growth rate of structurally diverse compounds from aqueous solution.
Mol. Pharm.
,
10(6):2381-2393.
84. Ilevbare, G.A., Liu, H., Edgar, K.J., and Taylor, L.S. (2012) Understanding polymer
properties important for crystal growth inhibition: impact of chemically diverse polymers
on solution crystal growth of ritonavir.
Cryst. Growth Des.
, 12(6):3133-3143.
85. Murdande, S.B., Pikal, M.J., Shanker, R.M., and Bogner, R.H. (2011) Aqueous solubility of
crystalline and amorphous drugs: challenges in measurement.
Pharm. Dev. Technol.
,
16(3):187-200.
86. Byrn, S.R., Pfeiffer, R.R., and Stowell, J.G. (1999)
Solid State Chemistry of Drugs
, Ssci Inc.,
West Lafayette, IN.
87. Newman, A., Knipp, G., and Zografi, G. (2011) Assessing the performance of amorphous
solid dispersions.
J. Pharm. Sci.
, 101(4):1355-1377.
88. Corrigan, O.I., Holohan, E.M., and Sabra, K. (1984) Amorphous forms of thiazide diuretics
prepared by spray drying.
Int. J. Pharm.
, 18(1-2):195-200.
89. Gupta, P., Kakumanu, V.K., and Bansal, A.K. (2004) Stability and solubility of
celecoxib-PVP amorphous dispersions: a molecular perspective.
Pharm. Res.
, 21(10):
1762-1769.
90. Wang, Q., Ma, D., and Higgins, J.P. (2006) Analytical method selection for drug product
dissolution testing.
Dissolut. Technol.
, 13(3):6-13.
91. USP (2004)
United States Pharmacopeia and National Formulary (USP 27-NF 22):
Dissolution
, United States Pharmacopeial Convention, Rockville, MD.
92. USP (2004)
United States Pharmacopeia and National Formulary (USP 27-NF 22): Drug
Release
, United States Pharmacopeial Convention, Rockville, MD.
93. Cohen, J.L., Hubert, B.B., Leeson, L.J., et al. (1990) The development of USP dissolution
and drug release standards.
Pharm. Res.
, 7(10):983
987.
94. USP (1998)
British Pharmacopeia: Dissolution of Solid Oral Dosage Forms
, Vol. 2, United
States Pharmacopeial Convention, Rockville, MD.
95. USP (2006)
United States Pharmacopeia and National Formulary (USP 41-NF 34): The
Dissolution Procedure—Development and Validation
, United States Pharmacopeial Con-
vention, Rockville, MD.
96. Boetker, J.P., Savolainen, M., Koradia, V., et al. (2011) Insights into the early dissolution
events of amlodipine using UV imaging and Raman spectroscopy.
Mol. Pharm.
,
8(4):1372-1380.
97. Ozaki, S., Minamisono, T., Yamashita, T., Kato, T., and Kushida, I. (2012) Supersaturation-
nucleation behavior of poorly soluble drugs and its impact on the oral absorption of drugs in
thermodynamically high-energy forms.
J. Pharm. Sci.
, 101(1):214-222.
98. Mehanna, M.M., Motawaa, A.M., and Samaha, M.W. (2010) Insight into tadalafil-block
copolymer binary solid dispersion: mechanistic investigation of dissolution enhancement.
Int. J. Pharm.
, 402(1-2):78-88.
99. Lust, A., Laidmäe, I., Palo, M., et al. (2013) Solid-state dependent dissolution and oral
bioavailability of piroxicam in rats.
Eur. J. Pharm. Sci.
, 48(1-2):47-54.
-
